METHODS article
Front. Cardiovasc. Med.
Sec. Atherosclerosis and Vascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1553735
This article is part of the Research TopicImmunity, Atherosclerosis and Cardiovascular Disease: An Interdisciplinary Approach to Cardiometabolic HealthView all 19 articles
Overview of Systematic Reviews on Chinese Patented Oral Medicines for Promoting Blood Circulation and Removing Blood Stasis Combined with Western Medicine in the Treatment of Coronary Heart Disease Angina Pectoris
Provisionally accepted
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the methodology quality, reporting quality, and evidence quality of systematic reviews and meta-analyses on Chinese patented oral medicines that promote blood circulation and remove blood stasis combined with conventional Western medicine in the treatment of coronary heart disease angina pectoris. The aim is to identify and address methodological issues in systematic reviews of Chinese patented oral medicines for promoting blood circulation and removing blood stasis in angina pectoris。 This study also offers methodological guidance for future research design and implementation, and provides a basis for clinical decision-making.Methods: A systematic search was performed using CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Embase, and Web of Science databases, covering the period from the inception of each database to July 18, 2024, and meta-analyses on randomized controlled trials were included. Methodological quality was evaluated using AMSTAR-2, reporting quality using PRISMA 2020, and evidence quality of the outcome indicators using GRADE.Results: Twenty meta-analyses were examined, involving a total of 41,231 patients with angina pectoris. The methodological quality of all studies was rated as "critically low," with notable deficiencies in the registration of the study protocol, study inclusion criteria, assessment of individual study risk of bias, evaluation of the likelihood of publication bias, and discussion of the effects of publication bias on the
Keywords: Chinese patented oral medicines, coronary heart disease, Angina Pectoris, Systematic review, Overview, Meta-analysis
Received: 31 Dec 2024; Accepted: 06 Jun 2025.
Copyright: © 2025 Chen, Liu, Wu, Deng, Peng, Xie and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yanming Xie, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Junjie Jiang, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.